Resources | Library

The clearest path to honoring Congress’ intent for 340B

Photo of host Jeremy Docken, group of poles with flags on them, a balance, and an eye.

Duplicate discounts remain a significant problem for the 340B Drug Pricing Program. Reports from the Office of Inspector General (OIG) and the U.S. Government Accountability Office (GAO) have highlighted the problems. However, there is a simple solution that can eliminate duplicate discounts: Convert 340B purchase discounts to rebates.

 

A 340B rebate will solve the duplicate discount problem, while providing benefits to all stakeholders. Most importantly, it would allow manufacturers and covered entities to work together in a transparent manner.

 

Download Webinar Presentation